InduPro Therapeutics Announces Strategic Investment from Sanofi and a Research Collaboration to Advance a Novel Bispecific for Autoimmune Disorders - InduPro
Summary
InduPro Therapeutics has secured a strategic equity investment from Sanofi along with a research collaboration focused on an autoimmune-disease program. The deal gives Sanofi a right of first negotiation on InduPro’s bispecific PD-1 agonist candidate, which is still in preclinical development. Both companies will work together on preclinical and IND-enabling research, with Sanofi providing funding for the effort. InduPro will use the partnership to advance its proximity-based discovery platform and therapeutic pipeline in cancer and autoimmune disease.
Funding
Amount
None
Total raised
Date
December 10, 2025
Announcement date
Investors
Aventis
Lead investors
Company
induprotx.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected